Cell cycle deregulation in B-cell lymphomas
Top Cited Papers
- 15 February 2003
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 101 (4) , 1220-1235
- https://doi.org/10.1182/blood-2002-07-2009
Abstract
Disruption of the physiologic balance between cell proliferation and death is a universal feature of all cancers. In general terms, human B-cell lymphomas can be subdivided into 2 main groups, low- and high-growth fraction lymphomas, according to the mechanisms through which this imbalance is achieved. Most types of low-growth fraction lymphomas are initiated by molecular events resulting in the inhibition of apoptosis, such as translocations affecting BCL2, in follicular lymphoma, or BCL10 and API2/MLT1, in mucosa-associated lymphoid tissue (MALT) lymphomas. This results in cell accumulation as a consequence of prolonged cell survival. In contrast, high-growth fraction lymphomas are characterized by an enhanced proliferative activity, as a result of the deregulation of oncogenes with cell cycle regulatory functions, such asBCL6, in large B-cell lymphoma, or c-myc, in Burkitt lymphoma. Low- and high-growth fraction lymphomas are both able to accumulate other alterations in cell cycle regulation, most frequently involving tumor suppressor genes such asp16INK4a , p53, andp27KIP1 . As a consequence, these tumors behave as highly aggressive lymphomas. The simultaneous inactivation of several of these regulators confers increased aggressivity and proliferative advantage to tumoral cells. In this review we discuss our current knowledge of the alterations in each of these pathways, with special emphasis on the deregulation of cell cycle progression, in an attempt to integrate the available information within a global model that describes the contribution of these molecular changes to the genesis and progression of B-cell lymphomas.Keywords
This publication has 199 references indexed in Scilit:
- NF-κB at the crossroads of life and deathNature Immunology, 2002
- Assessing TP53 status in human tumours to evaluate clinical outcomeNature Reviews Cancer, 2001
- Carma1, a CARD‐containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF‐κB activation1FEBS Letters, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Loss of p16/INK4A Protein Expression in Non-Hodgkin's Lymphomas Is a Frequent Finding Associated with Tumor ProgressionThe American Journal of Pathology, 1998
- Fas and Fas ligand: lpr and gld mutationsImmunology Today, 1995
- Expression in Non-Hodgkin's Lymphoma of thebcl-2 Protein Associated with the t(14;18) Chromosomal TranslocationNew England Journal of Medicine, 1988
- Multiple Recurrent Genomic Defects in Follicular LymphomaNew England Journal of Medicine, 1987
- Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18Cell, 1985
- Distinctive Chromosomal Abnormalities in Histologic Subtypes of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1982